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Summary 
Mice injected with anti-Fas antibody die within a few hours with total liver destruction due to 
massive apoptosis of hepatocytes. We show that this is preceded and accompanied by the se- 
quential  activation of cysteine proteases of the interleukin  1[3-converting enzyme (ICE) and 
CPP32 types in the cytosol of the hepatocytes, and that proCPP32 cleavage and enzymatic activity 
can be prevented by intravenous  injections  of the  tripeptide  N-benzyloxycarbonyl-Val-Ala- 
Asp-fluoromethylketone (Z-VAD.fmk), an inhibitor of ICE-like proteases. Four Z-VAD.fmk 
injections at 1-hour intervals abolished all signs of liver damage after anti-Fas antibody injection 
and resulted in 100% long-range recovery, without residual tissue damage, from a condition other- 
wise uniformly fatal within <3 hours. This treatment was effective even when delayed un- 
nl  some  liver DNA  degradation  was  already  detectable.  Injections  of the  tetrapeptide  Ac- 
YVAD.cmk, more specific for the ICE-like subfamily of cysteine proteases but less cell permeable, 
also gave protection, but at higher doses and when injections started before that of anti-Fas an- 
tibody. These observations afford a way of temporarily modulating a number of apoptotic pro- 
cesses in vivo and may have important therapeutic implications in some human diseases. 
T 
here  is  now  conclusive  evidence  that  the  process  of 
apoptosis  or  programmed  cell  death  (PCD)  results 
from the activation of members of a new family of cysteine 
proteases with a specificity of cleavage for aspartate in the 
P1 position. The decisive importance of this mechanism as 
an effector of PCD was revealed by the discovery that the 
ced-3  gene  of Caenorhabditis  elegans,  which  is  required  for 
cell death occurring during the normal development of this 
nematode (1), encodes for a protein related to the mamma- 
lian IL-l[3-converting enzyme (ICE)  (2),  an aspartate-spe- 
cific cysteine protease, and that, in certain conditions, over- 
expression  of ICE  itself in  mammalian  cells  can  lead  to 
apoptosis (3). Several other members of this protease family 
have now been identified and are presently subdivided into 
three subfamilies, each containing variants:  the ICE, CPP32 
(also  called  YAMA,  apopain,  or  priCE),  and  Ich-1  (or 
Nedd-2)  subfamilies;  all  these  enzymes are  synthesized  as 
inactive proenzymes requiring cleavage at specific Asp resi- 
dues to be transformed into  active proteases: thus,  at least 
some of these proteases can activate each other in the form 
of a  proteolytic  cascade  and/or  may undergo,  once  acti- 
vated, autoprocessing, allowing the potentially lethal ampli- 
fication of a minor imtial proteolytic process  (for review, 
see reference 4). Short peptides corresponding to the cleav- 
age site of some of these cysteine proteases have been used 
as inhibitors,  with the  Tyr-Val-Ala-Asp (YVAD)  and the 
Asp-Glu-Val-Asp (DEVD) motifs being rather specific in- 
hibitors of the ICE and CPP32 subfamilies, respectively (5). 
Provided their extracellular concentration is high enough, 
addition  of these or related inhibitory peptides to cell cul- 
tures prevents many forms, but not all, of PCD (6-8). 
One of the best studied ICE-related protease cascades in- 
volved in apoptotic cell death is that induced by the trig- 
gering of the Fas (APO-1,  CD95)  receptor on Fas-bearing 
cells  in vitro  (6,  7).  It has been shown that ICE-like pro- 
tease(s)  and CPP32 are activated in sequence after Fas stim- 
ulation  (9),  and that  the first proteolytic event may result 
from the  activation of a novel cysteine protease, which  is 
bound  to  the  FADD  or MORT  protein  (itself bound  to 
the intracellular domain of the Fas receptor) and has a Ced- 
3-like  structure  (10,  11).  The  accumulation  of activated 
CPP32-1ike  proteases  thus  appears  to  represent  a  down- 
stream event in this proteolytlc cascade. The most dramatic 
effect of Fas triggering in vivo as the result of a single injec- 
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sive apoptotic death of hepatocytes, which results in a few 
hours in total liver destruction and death (12). In this report 
we show that this event, which is also accompanied by the 
sequential activation of ICE- and CPP32-1ike proteases in 
the  cytoplasm of the  hepatocytes,  can be  completely and 
permanently prevented by  the  concomitant injections of 
high  doses  of the  tripeptide  benzyloxycarbonyl-Val-Ala- 
Asp  fluoromethylketone  (Z-VAD.fmk)  (13)  and  a  more 
specific  inhibitor  of  ICE-like  proteases,  acetyl-Tyr-Val- 
Ala-Asp chloromethylketone (Ac-YVAD.cmk). 
Materials and Methods 
Mice.  Mice  used  m  this  study were  3-4-wk-old (16-18  g) 
C57BL/6  females bred in the  animal facility  of the  University 
Medical Center of Geneva. 
Anti-Fas Antibody  and  ICE-like Inhibitor  Injections and  Histologic 
Examination.  Mice were injected intravenously  with 10 b~g of a 
purified hamster mAb 002)  against mouse Fas antigen (12) di- 
luted m 80 ~1 of 0.9 g/hter NaC1 solution. Z-VAD.fmk (Enzyme 
Systems Products,  Dublin, CA), Z-D.cmk, and Ac-YVAD.cmk 
peptides  (BACHEM Feinchemlkalien AG, CH), were dissolved 
m  DMSO at a concentration of 100 mg/ml. All peptlde injec- 
tions were intravenous and started 5 rmn after antl-Fas  antibody 
injection, except  when indicated otherwise.  Mice were killed at 
various nines or autopsmd immediately after death, and fragments 
of ussues were fixed m wvo with 4% paraformaldehyde  in PBS, 
embedded in paraffin, and 5-txm sections were stained with he- 
matoxylin and eosm. 
Western Blot Analysis.  Minced liver fragments were homoge- 
nized at 4°C with RIPA buffer  (PBS, 1% NP-40, 0.5% sodium 
deoxycholate,  0.1%  SDS) containing 2  b~g/~l  aprotinm and  1 
mM PMSF.  After centrifugation at  15,000 g, 30 b~g of superna- 
tant protein was loaded per lane on 10% polyacrylamide  gels and 
electrophoresed.  After  transfer  to  nitrocellulose membranes and 
exposure  to 5% nonfat milk TBS-T (20 mM Trts HCI, 500 mM 
NaC1, pH 7.5,  and Tween 0.1%), the washed  membranes were 
incubated for 1 h at 20°C with a rabbit ann-murine  ICE at a 1:3,000 
dilution (kind gnft ofJ. Tschopp, Insntut de Biochlmie, ISKEC, 
Lausanne, Switzerland), a rabbit ann-ICE pl0 at a dilution of 1:200 
(M20; Santa Cruz Blotech Inc., CA). a rabbit anti-human CPP32 
p17 at a dilution of 1:7,500  (kind gift of D.  Nicholson, Merck 
Frosst,  Pointe-Claire-Dorval, Quebec,  Canada),  or  anu-LAP3 
(kind gift  of V.M.  Dlxit,  University of Michigan, Ann Arbor, 
MI). Goat anti-rabbit IgG (Santa Cruz Biotech. Inc., Santa Cruz, 
CA) was used as second  annbody at a concentration of 400-800 
ng/ml. Membranes were washed  with TBS-T, incubated in en- 
hanced chemiluminescence detectmn reagents  (Amersham  Inter- 
national, Amersham, UK) at room temperature, and exposed  to 
Hyperfilm-MP films (Amersham International). 
Fluorometric Analyses.  Liver protein extracts were prepared by 
Dounce homogemzatmn of 20 mg of tissue in a hypotonlc buffer 
(25  mM Hepes,  pH  7.5,  5 mM MgCI>  1 mM EGTA,  1 mM 
PMSF,  1  p~g/mi leupeptln and aprotinln). Homogenates were 
centrifuged at 15,000 rpm for  10 rain and the supernatants  were 
used. 20 ~g of the extracted proteins was incubated with the fluo- 
rescent  substrates  Z-YVAD-AFC or  Z-DEVD-AFC  (Enzyme 
Systems Products)  at a concentration of 25 mM in 50 mM Hepes, 
l%  sucrose,  0.1%  CHAPS  (3-([3-cholamidopropyl]-dimeth- 
ylammonio)-l-propane-sulfonate),  and 5 mM &thiothreitol in a 
volume of 1 rnl. The fluorescence  of the cleaved substrates was 
determined using a spectrofluorometer set at an excitation wave- 
length of 400 nm and an emission wavelength of 505 nm. One 
unit corresponds  to the activity that cleaves l pmol of the respec- 
tive fluorescent substrate at 25°C in 30 mln. 
DNA Fragmentation  Detection.  For the  detecnon of ohgonu- 
cleosomes,  a cell death detection ELISA kit (Boehnnger Mann- 
heim AG,  Rotkreuz,  Switzerland)  was  used  according  to  the 
manufacturer's instructions adapted  for  the  use  of tissue  frag- 
ments. Briefly,  small pmces  of liver (25-40 mg)  were weighed 
and homogemzed in the provided lysls buffer,  incubated for 30 
mm at room temperature, and after  a  10-ram centrifugatlon at 
2,000 rpm, 20 hal of the supernatant was submitted to the ELISA 
test.  For electrophoretic  detectmn of DNA  cleavage  products, 
liver extract  supernatants  were precipitated  overmght w~th iso- 
propanol. The 15,000-rpm pellets were then digested  overmght 
with protemase  K, extracted  with phenol-chloroform-isoamylal- 
cohol, treated w~th 1KNase A, precipitated  with ethanol, and sub- 
mitted to electrophoresls  in 2% agarose gels. 
Senml Aminotransferase Determination.  Quantification of alanlne 
aminotransferase  (ALAT) and aspartate aminotransferase  (ASAT) 
in the sera was made with a standard  chnical automatic analyzer 
(model 7150; Hitachi). 
Results 
Intravenous injection of 10 bLg of the Jo2 anti-Fas mAb 
was  used throughout these  experiments. This amount in- 
variably killed all 15-18-g C57BL/6 mice within 3 h; when 
killed after 2  h,  all mice already had  a  severely shrunken, 
massively hemorragic liver, with extensive lesions of hepa- 
tocyte apoptosis on histologic sections (Fig.  1 b, compared 
with normal hver, Fig.  l  a).  Evidence of hepatocyte dam- 
age  became  clearly  detectable  only  after  60  min;  at  this 
time,  blood levels  of liver aminotransferases were  almost 
unchanged (Fig.  2  a),  and in liver lysates DNA  oligonu- 
cleosomes characteristic of apoptosis were  only detectable 
by a  sensitive immunologic assay  (Fig.  2  b);  after 60  rain, 
the blood aminotransferases rapidly xncreased to very high 
levels until death (Fig. 2 a) and DNA fragmentation in the 
liver, as detected on agarose gels, became massive (Fig. 2 b). 
Proteolytic  activity of the  ICE  and  CPP32  type  was  as- 
Figure 1.  Liver  histology,  detail. (a) Normal mouse. (b) Mouse killed  2 h 
after m3ecuon of antl-Fas antibody. The architecture of the hver paren- 
chyma is destroyed with hemorrhagic focl, several  apoptotm hepatocytes are 
seen. (c) Mouse killed  2 h after antibody  m  lectlon, followed  after 5 mm by 
Injection of 500 brg Z-VAD.fmk. Original magmficanon  X400. 
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Figure  2.  (a)  Prevention by Z-VAD.fmk mjecnons of the increase of ASAT (/eft) and ALAT (ngh 0  concentrations in the serum after Fas-induced 
hver damage. A, control mice. BI, treated mice. (b) Preventmn ofFas-lnduced hver DNA fragmentation after Z-VAD.fmk m3ections. (Left) DNA frag- 
mentanon assay (nucleosome). Normal liver (left column); maddle: liver 1 h after antl-Fas annbody m]ectmn (middle column),  effect of Z-VAD.fmk rejection 
5 mln after anti-Fas mjecnon (right column).  (Right) DNA laddenng on agarose gel 2 h after ann-Fas rejections,  with or without Z-VAD,fmk m,  lectmn. (c) 
Actlvauon of ICE-like and CPP32-1ike proteases dunng Fas-mduced liver damage m vivo, using cleavage assays of the fluorescent substrates Z-YVAD- 
AFC (for ICE-like proteases; left) and Z-DEVD-AFC (for CPP32-hke proteases; right) m the presence of the same liver cytosohc  extracts used for both 
assays. A, control. II, Z-VAD-treated mice. 
sessed  in  the liver lysates  of mice  killed at  30-min  intervals 
after antibody  injection,  by using as substrates  the  Z-YVAD- 
AFC  and  Z-DEVD-AFC  peptides,  which  correspond,  re- 
spectively,  to  an  ICE  and  a  CPP32  cleavage  site  (5).  ICE- 
like activity rapidly rose in liver lysates after 30 min but in a 
transient  way,  and  returned  to  normal values  at  90  min;  in 
contrast,  CPP32-1ike  activity  rose  continuously  until  120 
rain,  at  the  time  of very  severe  hepatocyte  damage  (Fig.  2 
c).  Cleavage  of prolCE  and proCPP32  was also directly ex- 
plored  by  Western  blotting  of the  liver  lysates  (Fig.  3).  A 
very  limited  cleavage  of prolCE,  indicated  by  the  appear- 
ance  of a  36-kD  band  (14),  was  detectable  after  60  min;  a 
decrease  in proCPP32  was  observed  after  60  rain  and  cor- 
responded to a limited cleavage of the proenzyme  as shown 
by  the  detection  of a  17-kD  band  of weak  intensity.  No 
LAP-3,  a  protease  of  the  CPP32  family,  was  detectable, 
suggesting that  this  enzyme is  not present in the liver  (I 5). 
The  nuclear  poly(ADP-ribose)  polymerase,  a  substrate  for 
CPP32  whose  cleavage  is  characteristic  of apoptotic  nuclei 
(16),  could  not  be  clearly  visualized,  perhaps  because  this 
protein  is  less  abundant  in  the  nuclei  of the  nondividing 
hepatocytes  than  m  those  of dividing cells,  where  it is usu- 
ally observed. 
Mice  were  then  injected  with  anti-Fas  antibody  fol- 
lowed  5  rain  later  by  intravenous  injections  of  various 
amounts of the Z-VAD.fmk  peptide.  In a pilot experiment, 
two mice injected with  1 mg or 0.25 mg (about 2  or 0.5  DM, 
respectively)  of the  peptide  survived  15  and  7  h,  respec- 
tively, but had severely damaged liver at autopsy,  compara- 
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Figure  3.  Western blots for the detection of CPP32 and ICE m hver 
cytosohc extracts.  (a) Anti-CPP32 antibody, in addiuon to the p32 band 
of proCPP32, a band of pt7 is present in the liver 90 rain after antibody 
injection  and is  not detectable m  the liver lysates from a Z-VAD.frnk- 
treated mouse. Exposure nine of the film was 5 nan for p45 and 15 min 
for p17.  (b) Anti-ICE annbody: a faint band (p36,  arrow), corresponding 
to the lmtial processing  of proICE (p45) is distlngmshable  m hver lysates 
after anu-Fas antibody rejection. Whereas in other experiments the faint 
p36 band was seen after 60 rain, here ~t was more clearly seen in the 120- 
mln hver lysate. 
2069  Rodnguez et al.  Bnef Defimtive Report ble to that of control mice, which  died within  3  h;  three 
mice injected with 0.5 mg of the peptide were killed after 2 h 
and  had  macroscoplcally  and  histologically  normal  liver 
(Fig.  1 c). On this basis, it was decided to prolong exposure 
to the protecting peptide by using the following schedule: 
an initial injection of 0.25 mg, followed by three injections 
of 0.1  mg at  1-h intervals.  Three  experiments were then 
performed, corresponding to a total of 15 mice injected ac- 
cording to  this  schedule  and  20  control  mice:  all  control 
mice  died  within  3  h,  whereas  the  15  Z-VAD-injected 
mice survived and  were in  apparent good health  days or 
weeks later.  In a last experiment involving five mice and 
their controls,  this peptide injection  schedule was delayed 
until 65 rain after anti-Fas antibody injection, i.e., at a time 
when  apoptotic  DNA  fragmentation  in  the  liver had  al- 
ready started (Fig. 2 b). Four out of the five Z-VAD-injected 
mice survived and one died after 10 h with a severely dam- 
aged liver. 
Mice protected by this injection schedule started 5 rain 
after antibody injection were then killed or bled at different 
times to follow the cysteme protease activity of their liver 
and  their blood level of aminotransferases. Unexpectedly, 
the  first  wave  of Z-YVAD-AFP  cleavage  activity  of the 
hepatocyte cytosol was not decreased (Fig. 2 c,/eft);  in con- 
trast,  the  Z-DEVD-AFP  cleavage  activity was  decreased 
and had returned to baseline levels after 90 rain,  at a time 
when unprotected mice showed a very high activity (Fig. 2 c, 
right).  In agreement with this last observation, no cleavage 
of CPP32  was  detected on Western  blots  (Fig.  3).  Blood 
aminotransferase levels showed  only a very small increase 
compared with that of unprotected mice and were at the 
baseline levels 4  d later (Fig.  2  a).  Histologic examination 
of the liver obtained at various times of sacrifice 1 to several 
days later showed no signs  of damage, indicating full pro- 
tection. In contrast, one of the four mice surviving after the 
65-rain-delayed Z-VAD injection schedule mentioned above 
and sacrificed 1 d later showed histologically focal areas  of 
liver necrosis;  these lesions can certainly heal, because the 
three other surviving mice of this group were in apparent 
good health in the following weeks. The histologic appear- 
ance of various organs (heart, spleen, gut, lung, brain, intes- 
tine) was also normal, suggesting that the injected peptides, 
at the dosage used, had no toxic effect. It should be added 
that protection of the liver in all these experiments cannot 
be  attributed  to  an  unexpected  effect  of a  Z-xmk com- 
pound  on hepatocytes, since mice injected with the same 
amount  of the  Z-D.cmk compound  died,  as  did  control 
mice, with identical lesions. 
A  more  specific  inhibitor  of cysteine  proteases  of the 
ICE subfamily is  the  tetrapeptide Ac-YVAD.cmk.  In cell 
culture, it is, however, more difficult to inhibit Fas-medi- 
ated  apoptosis with  this  peptide.  Using mouse  Fas-trans- 
fected W4 and P815  cell hnes, we have observed that Fas- 
mediated  apoptosis,  which  is  otherwise  almost  complete 
within 4 h, is highly inhibited at concentration of 100 ~M 
by Z-VAD.-fmk, but only partially inhibited in the presence 
of 300-600  ~M  Ac-YVAD.fmk,  perhaps  because  of the 
lesser  cell  permeability of the latter  compound.  Two mice 
were injected with Ac-YVAD.cmk according to the sched- 
ule described above, but with a double amount (i.e.,  initial 
dose of 0.5 rag): one mouse died after 7.5 h  and the other 
survived (but its liver was not examined). Because the in- 
tracellular  availabili  W  of the  peptlde  may be  slower,  the 
peptide administration schedule was applied to one mouse 
starting  15  rain before anti-Fas injection;  this  mouse  sur- 
vived and had no gross or histologic liver lesions when sac- 
rificed 1 d later. In spite of their small number, these last re- 
sults  conclusively show that administration  of a peptide of 
more restricted anti-ICE specifici  W is capable of preventing 
Fas-mediated apoptosis in vivo. 
Discussion 
The cysteine protease activity triggered in hepatocytes in 
vivo by anti-Fas antibody injections showed a pattern of se- 
quential  activity comparable to  that  observed during  Fas- 
induced  apoptosis of mouse W4 cells  (9),  with a transient 
ICE-like activity observed first, followed by a gradually in- 
creasing CPP32-1ike activity. However, whereas on West- 
ern blots some degree of cleavage ofprolCE was observed 
after 45 min and ofproCPP32 after 90 rain, these cleavages 
were much weaker than those observed on Western blots 
of W4  and  P815  cells  undergoing  in  vitro  Fas-induced 
apoptosis  (Ody,  C.,  K. Matsuura,  and P.  Vassalli,  unpub- 
lished  observation).  This  observation  suggests  that  other 
members  of the  Ced-3  cysteine  proteases family may be 
more preferentially involved in hepatocyte PCD;  the liver 
appears to be especially rich in  ICErej  II and III proteases 
(belonging to the ICE subfamily) and in Mch2  (considered 
to belong to the CPP32  subfamily), the cleavage of which 
could not be explored because of the lack of relevant anti- 
bodies. Some of these last proteases appear to be more sus- 
ceptible to some protease inhibitors than other members of 
their  subfamily  (17).  This  may  explain  why  hepatocytes 
may be protected  by the  Z-VAD  and  YVAD  inhibitory 
pepfdes more easily than W4 or P815 cells, because it is not 
likely that the concentration of these peptides required for 
in vitro prevention of Fas-mediated apoptosis of these cell 
lines, as described above, had been durably achieved in vivo. 
The observation that ICE-like protease activity was not in- 
hibited in the liver of the Z-VAD protected mice, in con- 
trast to CPP32-1ike activity, might suggest that Z-VAD.fmk 
is a better inhibitor of the latter enzymes. However, because 
it  has  been  observed  that  Z-VAD.fmk inhibits  poorly in 
vitro CPP32-1ike  proteolysis once activated  (18),  it is more 
likely that the failure of Z-VAD injections, with the injec- 
tion schedule used, to efficiently inhibit the early ICE-like 
protease activity, in contrast to the late CPP32-1ike activity, 
results from an insufficiently high  lntracellular  concentra- 
tion of the inhibitory peptides after the first injection.  The 
observation that injections  of the Ac-YVAD.cmk peptlde 
also completely prevented liver damage when started before 
anti-Fas antibody injecuon strongly supports the notion of 
a PCD-mduclng proteolytic cascade  that can be interrupted 
2070  In Vlvo Prevention of Fas-induced Death at its early stages.  However, the first element of the cascade 
in  Fas-induced  PCD  is  the  activation  of  the  MACH- 
FLICE cysteine  protease,  bound  to  the  MORT(FADD)- 
Fas protein complex (10,  11). This protease, which belongs 
to  the  CPP32  subfamily,  cleaves  after  its  activation  the 
Z-DEVD- but not the Z-YVAD-AFC peptide  (10). Thus, 
the  early  autoamplification  steps  of the  cysteine  protease 
cascade,  rather  than  the  probable  initial  proteolytic event, 
appear to be the  targets  of the  inhibitory peptides  used to 
prevent hepatocyte death in these experiments. 
An intriguing  question  raised by the  obvious instability 
and rapid decrease in vivo of the inhibitory peptides is how 
full  and  permanent  protection  against  liver  damage  and 
death  can be  achieved by a  few hours  of protection  after 
injection  of an  amount  as  high  as  10  ixg of agonist  anti- 
body, which is not expected to diffuse very rapidly out of 
the vascular compartment.  At least three not mutually ex- 
clusive possibilities must be considered, which are presently 
under  study:  rapid  removal  of the  antibody by Fas  mole- 
cules makes it drop to a level insufficient to trigger signifi- 
cant  hepatocyte  damage;  the  level  of Fas  molecules  on 
hepatocytes may also drop and lead to the same result; pro- 
tected hepatocytes may undergo metabolic changes making 
them more resistant  to Fas-mediated death,  as occurs with 
TNF-sensitive  cells  first exposed to a sublethal  concentra- 
tion of TNF (19). 
The possibility of preventing or attenuating in vivo ful- 
minant liver damage resulting from liver apoptosis has im- 
portant  therapeutic  implications  in humans.  It is generally 
assumed  that  fulminant  hepatitis  occurring  during  viral 
hepatitis is mediated by cytotoxic T  lymphocytes. The cy- 
totoxic activity of these cells is mediated through the per- 
forin-granzyme and/or  the  Fas pathway  (20);  the  mecha- 
nisms  of cell  death  are  probably  common  in  these  two 
pathways because granzyme B,  a serine  protease  with Asp 
specificity  of cleavage,  is  an  efficient  activator  of CPP32 
(21-23).  The temporary perfusion of peptides with a high 
cell permeability  designed to be potent irreversible  inhibi- 
tors of the ICE-like proteases (24, 25) may thus be of great 
therapeutic  benefit  if these  compounds  show  no  general 
toxicity. In the very limited pattern of injection used in the 
present  experiments,  no signs of toxicity were  observed; 
Z-VAD.fmk  in  vitro  at  a  concentration  of 100  ~M  has 
been found not to be toxic for at least 48 h  (26).  Our ob- 
servation that Z-VAD.fmk injections protected mice from 
massive liver destruction and death even when delayed un- 
til  a  time  when  apoptotic  DNA  cleavage  was  detectable 
strengthens the potential therapeutic value of this approach. 
A  number of other acute clinical situations are probably ac- 
companied by cell death, especially harmful in tissues  where, 
in  contrast  to  hepatocytes,  regeneration  does  not  occur, 
such as the nervous tissue;  in vitro,  Z-VAD.fmk has been 
found to protect neurons from certain apoptotic-inducing 
conditions  (27).  Finally,  perfusion of cysteine protease  in- 
hibitory peptides may be also of experimental use to detect 
in vivo the involvement of PCD in physiological or patho- 
logical conditions, as well as to explore the mechanism un- 
derlying various PCD, because in vitro not all PCD-induc- 
ing conditions display sensitivity to inhibitory peptides such 
as Z-VAD.fmk. 
We thank Ms. Joan Stalder, Ms. Genevieve Leyvraz and Mr.  Christian Vesta for techmcal assistance, Ms. J. 
Ntah for secretarial work, Mr. E. Denkmger and Mr. J.-C. R.umbeli for photographic work, and Drs. J. 
Tschopp, D. Nicholson, and V.M. Dixit for the gift of antibodies. 
This work was supported  by grant 31-37516.93  from the Swiss National Foundation. 
Address correspondence to Pierre  Vassalli, Department of Pathology, Centre M6dical Universitaire,  1 rue 
Michel Server, CH 1211 Geneva 4, Switzerland. 
Received for publication 8July  1996 and in revised  form 6 August 1996. 
References 
1. Yuan, J., S. Shaham, S. Ledoux, H.M. Ellis, and H.R. Hor- 
vitz.  1993.  The  C.  elegans cell  death gene ced-3 encodes a 
protein similar to mammalian interleukin-l[3-converting en- 
zyme. Cell. 75:641--652. 
2. Thornberry, N.A., H.G. Bull, J.P,,. Calaycay, K.T. Chapman, 
A.D. Howard, M.J.  Kostura, D.K. Miller,  S.M. Molineaux, 
J.K. Weldner, J. Aunins et al.  1992.  A novel heterodimeric 
cysteine  protease  is required for interleukin-l[3 processing m 
monocytes. Nature (Lond.). 356:768-774. 
3.  Miura, M., H. Zhu, R. P,.otello, E.A. Hartwleg, andJ. Yuan. 
1993. Induction ofapoptosis in fibroblasts by IL-l[3-convert- 
ing  enzyme,  a  mammalian  homolog of the  C.  elegans cell 
death gene ced-3. Cell. 75:653-660. 
4.  Chinnalyan,  A.M.,  and  V.M.  Dixit.  1996.  The  cell-death 
machine. Curr. Biol. 6:555-562. 
5.  Nicholson,  D.W.,  A.  All,  N.A.  Thomberry, J.P.  Valllan- 
court, C.K. Ding, M.  Gallant,  Y.  Gareau,  P.R.  Griffin,  M. 
Labelle, Y.A. Lazebnik et al.  1995.  Idennfication and inhibi- 
tion  of the  ICE/CED-3 protease  necessary  for mammalian 
apoptos]s. Nature (Lond.). 376:37-43. 
6.  Enari,  M., H. Hug, and S. Nagata.  1995.  Involvement of an 
ICE-like protease  in Fas-mediated apoptosis.  Nature (Lond.). 
375:78-81. 
7.  Los,  M.,  M.  Van de  Craen,  L.C.  Penning,  H.  Schenk,  M. 
2071  P,.odriguez et al.  Brief Definitive  Report Westendorp, P.A. Baeuerle, W. Dr6ge, P.H.  Krarnmer, W. 
Fiers,  and  K.  Schulze-Osthoff.  1995.  Requirement  of an 
ICE/CED-3  protease  for  Fas/APO-l-mediated apoptosis. 
Nature (Lond.).  375:81-83. 
8.  Cain, K., S.H. Inayat-Hussain, C. Couet, and G.M. Cohen. 
1996.  A  cleavage-site-directed  inhibitor  of  interleukm- 
l~-converting  enzyme-like proteases  inhibits  apoptosls  m 
primary cultures of rat hepatocytes. Biochem. J. 314:27-32. 
9. Enan,  M.,  R.V.  Talanian,  W.W.  Wong,  and  S.  Nagata. 
1996.  Sequential activation of ICE-like and CPP32-1ike pro- 
teases  dunng  Fas-mediated apoptosis.  Nature  (Lond.).  380: 
723-726. 
10. Boldin, M.P, T.M. Goncharov, Y.V. Goltsev, and D. Wallach. 
1996.  Involvement  of MACH,  a  novel  MORT1/FADD- 
interacting  protease,  in  Fas/APO-1-  and  TNF  receptor- 
induced cell death. Ceil. 85:803-815. 
11. Muzio, M., A.M. Chinnaiyan, F.C. Kischkel, K. O'Rourke, 
A. Shevchenko, J. Ni, C. Scaffidi, J.D. Bretz, M. Zhang, lZk. 
Gentz et al. 1996.  FLICE, a novel FADD-homologous ICE/ 
CED-3-1ike protease, is recruited to the CD95 (Fas/APO-I) 
death-inducing signaling complex. Cell. 85:817-827. 
12. Ogasawara, J., 1L. Watanabe-Fukunaga, M. Adachl, A. Mat- 
suzawa, T. Kasugai, Y. Kitamura, N.  Itoh, T.  Suda, and S. 
Nagata. 1993.  Lethal effect of the anti-Fas antibody in mice. 
Nature (Lond.). 364:806-809. 
13. Dolle, R.E.,  D.  Hoyer,  C.V.C.  Prasad,  S.J.  Schmidt,  C.T. 
Helaszek, R.E.  Miller, and M.A. Ator.  1994.  P1  Aspartate- 
based peptide ot-((2,6-dichlorobenzoyl)oxy)methyl  ketones as 
potent time-dependent inhibitors of interleukln-tl3-convert- 
ing enzyme.J, filed.  Chem. 37:563-564. 
14. Ramage, P., D. Cheneval, M. Chvei, P. Graft, IL. Hemmig, R.. 
Heng, H.P. Kocher, A. MacKenzie, K. Memmert, L. 1Levesz, 
and W. Wlshart.  1995.  Expression, refolding, and autocata- 
lytic proteolytic processing of the interleukln-l[3-converting 
enzyme precursor.J. Biol.  Chem. 270:9378-9383. 
15. Duan, H., A.M. Chinnaiyan, P.L. Hudson, J.P. Wing, W.W. 
He, and V.M. Dixit.  1996.  ICE-LAP3, a novel mammalian 
homologue  of the  Caenorhabditis  elegans cell death  protein 
Ced-3  is  activated dunng  Fas- and  tumor  necrosis factor- 
induced apoptosis.J. Biol.  Chem. 27l:1621-1625. 
16. Lazebnik, Y.A., S.H. Kaufmann, S. Desnoyers, G.G. Poirier, 
and  W.C.  Earnshaw.  1994.  Cleavage of poly(ADP-ribose) 
polymerase by a protemase with properties like ICE. Nature 
(Lond.). 371:346-347. 
17. Liu, X., C.N. Kim, J. Pohl, and X. Wang. 1996.  Purification 
and characterization of an interleukin-1  [3-converting enzyme 
farmly protease that activates cysteine protease P32 (CPP32). 
J. Biol.  Chem. 271:13371-13376. 
18. Slee,  E.A.,  H.  Zhu,  S.C.  Chow,  M.  MacFarlane,  D.W. 
Nicholson, and G.M. Cohen. 1996. Benzyloxycarbonyl-Val- 
Ala-Asp (OMe) fluoromethylketone (Z-VAD.FMK) inhibits 
apoptosls by blocking the processing of CPP32.  Biochem. J. 
315:21-24. 
19. Wong, G.H.W.,J.H. Elwell, L.W. Oberley, and D.V. Goed- 
del.  1989.  Manganous  superoxlde dismutase is essenual for 
cellular resistance  to  cytotoxicxty of tumor  necrosis factor. 
Cell.  58:923-931. 
20.  Kagi, D., F. Vlgnaux, B. Ledermann, K. Burki, V. Deprae- 
tere, and S. Nagata. 1994.  Fas and perforin pathways as major 
mechamsms  of T  cell-mediated cytotoxicity. Science (Wash. 
DC). 265:528-530. 
21. Darmon, A.J., D.W.  Nicholson, and 1K.C. Bleackley. 1995. 
Activauon of the apoptotic protease CPP32 by cytotoxic T-cell- 
derived granzyme B. Nature (Lond.).  377:446-448. 
22. Martin, S.J.,  G.P. Amarante-Mendes, L.  Shi, T.H.  Chuang, 
C.A. Casiano, G.A. O'Brien, P. Fitzgerald, E.M. Tan, G.M. 
Bokoch, A.H. Greenberg, and D.1L. Green. 1996. The cyto- 
toxic cell protease granzyme B imtiates apoptosis m a cell-free 
system by proteolytlc processing and activation of the ICE/ 
CED-3 family protease, CPP32, via a novel two-step mecha- 
msm. EMBO (Eur.  Mol.  Biol.  Organ.).J.  15:2407-2416. 
23.  Quan, L.T., M. Tewarl, K. O'Rourke, V. Dixit, S.J. Smpas, 
G.G. Polrier, C. Ray, D.J. Pickup, and G.S. Salvesen.  1996. 
Proteolytlc activation of the cell death protease Yama/CPP32 
by granzyme B. Proc. Natl. Acad.  Sci.  USA.  93:1972-1976. 
24. Nicholson, D.W.  1996.  ICE/CED3-1ike proteases as thera- 
peutic targets for the control of inappropnate apoptosis. Nat, 
Biotech.  14:297-301. 
25. Thornberry, N.A., E.P.  Petersen, J.J.  Zhao,  A.D.  Howard, 
PAL. Griffin, and K.T. Chapman. 1994.  Inacuvauon ofmter- 
leukin-l[3  convertang  enzyme  by  peptide  (Acyloxy)methyl 
ketones. Biochemistry.  33:3934--3940. 
26. Jacobson,  M.D.,  M.  Weil,  and  M.C.  Raft.  1996.  Role  of 
Ced-3/ICE-family proteases in  staurosporine-induced pro- 
grammed cell death._].  Cell Biol.  133:1041-1051. 
27. Mllligan, C.E.,  D.  Prevette,  H.  Yaginuma,  S.  Homma,  C. 
Cardwell, L. C. Fritz, K.J. Tomaselli, R.W. Oppenhelm, and 
L.M. Schwartz. 1995.  Pepude inhabltors of the ICE protease 
family arrest programmed cell death of motoneurons in vivo 
and an vltro. Neuron.  15:385-393. 
2072  In Vlvo Prevention of Fas-induced Death 